RHYTHM PHARMACEUTICALS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$57M
↑+36.9% +$15Mvs FY2024 (Q4)
Gross Profit
$52M
↑+37.9% +$14Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $57M | $42M |
| COGS | $5M | $4M |
| Gross Profit | $52M | $38M |
| R&D | $42M | $41M |
| SG&A | $57M | $38M |
| D&A | $0 | $0 |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · RYTM · Comparing FY2025 (Q4) vs FY2024 (Q4)